CD38 and triple-A syndrome: The results showed that SMC-specific deletion (CD38SKO) of CD38 significantly reduced the morbidity of AngII-infusion-induced AAA from 86.7% (13/15 mice) of CD38Fl/FlApoe−/− mice to 33.3% (3/9 mice) of CD38SKOApoe−/− mice; in comparation, the sham operation group had no AAA formation (Figure 2A,B).